Inventor · disambiguated record
Steven Richard Witowski
Also filed as: WITOWSKI STEVEN · WITOWSKI STEVEN RICHARD
10 granted patents·15 pending applications·94 citations·filing 2009–2023
89Inventor score
Files withIRONWOOD PHARMACEUTICALS INC8CELGENE AVILOMICS RES INC5FRETZEN ANGELIKA4CELGENE CAR LLC3FOREST LAB HOLDINGS LTD3
Top patents by PatentIndex Score
25 records- 0194US8563568B2Besylate salt of a BTK inhibitorWITOWSKI STEVEN RICHARD·Filed 2011·Granted Oct 22, 2013·46 cites·14 claims
- 0291US9604936B2Besylate salt of a BTK inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Mar 28, 2017·13 cites·14 claims
- 0390US8748573B2Formulations comprising linaclotideFRETZEN ANGELIKA·Filed 2010·Granted Jun 10, 2014·8 cites·10 claims
- 0489US9108927B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2013·Granted Aug 18, 2015·9 cites·20 claims
- 0588US9540335B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE AVILOMICS RES INC·Filed 2015·Granted Jan 10, 2017·5 cites·20 claims
- 0686US8802628B2Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administrationFRETZEN ANGELIKA·Filed 2009·Granted Aug 12, 2014·7 cites·26 claims
- 0785US10005738B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2017·Granted Jun 26, 2018·3 cites·20 claims
- 0883US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0982US10570099B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2018·Granted Feb 25, 2020·2 cites·22 claims
- 1078US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1175US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1274US11292772B2Salts of an epidermal growth factor receptor kinase inhibitorCELGENE CAR LLC·Filed 2020·Granted Apr 5, 2022·0 cites·14 claims
- 1370US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1469US9364476B2Methods of treating a Bruton's Tyrosine Kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2012·Granted Jun 14, 2016·1 cites·26 claims
- 1565US2019029967A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1662US2012009225A1Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral AdministrationFRETZEN ANGELIKA·Filed 2009·Application pending·0 cites
- 1761US2013273169A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 1860US2013190239A1Formulations Comprising LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1960US2015132375A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2054US2015031632A1Orally Disintegrating Compositions of LinaclotideFOREST LAB HOLDINGS LTD·Filed 2014·Application pending·0 cites
- 2151US2014349948A1Treatment of Chronic ConstipationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 2251US2012039949A1Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral AdministrationFRETZEN ANGELIKA·Filed 2009·Application pending·0 cites
- 2345US2016287588A1Methods of treating a bruton's tyrosine kinase disease or disorderCELGENE AVILOMICS RES INC·Filed 2016·Application pending·0 cites
- 2443US2013059797A1Linaclotide for the Treatment of Chronic ConstipationJOHNSTON JEFFREY·Filed 2010·Application pending·0 cites
- 2536US2013012454A1Orally Disintegrating Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Steven Richard Witowski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →